1415128-08-3

Basic information

• Product Name: 3-(5-(3-chloro-2-(((2',4'-dichloro-[1,1'-biphenyl]-4-yl)amino)methyl)-5-(trifluoromethyl)phenyl)picolinamido)propanoic acid
• Synonyms: 3-(5-(3-chloro-2-(((2',4'-dichloro-[1,1'-biphenyl]-4-yl)amino)methyl)-5-(trifluoromethyl)phenyl)picolinamido)propanoic acid
• CAS NO: 1415128-08-3
• Molecular Weight: 622.858
• Mol File: 1415128-08-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-(5-(3-chloro-2-(((2',4'-dichloro-[1,1'-biphenyl]-4-yl)amino)methyl)-5-(trifluoromethyl)phenyl)picolinamido)propanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(5-(3-chloro-2-(((2',4'-dichloro-[1,1'-biphenyl]-4-yl)amino)methyl)-5-(trifluoromethyl)phenyl)picolinamido)propanoic acid(1415128-08-3)
• EPA Substance Registry System: 3-(5-(3-chloro-2-(((2',4'-dichloro-[1,1'-biphenyl]-4-yl)amino)methyl)-5-(trifluoromethyl)phenyl)picolinamido)propanoic acid(1415128-08-3)

Safety Data

• Hazardous Substances Data: 1415128-08-3(Hazardous Substances Data)

Upstream product

• 1415129-85-9 ethyl 3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinamido)propanoate 
• 1415130-44-7 N-(2-bromo-6-chloro-4-(trifluoromethyl)benzyl)-2',4'-dichloro-[1,1'-biphenyl]-4-amine 
• 1274070-41-5 Ethyl 3-(5-bromopicolinamido)propanoate 
• 30766-11-1 5-bromoisonicotinic acid 
• 1415130-45-8 ethyl 3-(5-(3-chloro-2-(((2',4'-dichloro-[1,1'-biphenyl]-4-yl)amino)methyl)-5-(trifluoromethyl)phenyl)picolinamido)propanoate 
• 1415130-43-6 2-bromo-6-chloro-4-(trifluoromethyl)benzaldehyde 
• 1415130-42-5 2-bromo-6-chloro-4-(trifluoromethyl)benzonitrile 
• 109919-26-8 2-bromo-6-chloro-4-(trifluoromethyl)aniline 
• 175205-55-7 1-bromo-3-chloro-2-iodo-5-(trifluoromethyl)benzene 
• 939757-52-5 2',4'-dichloro-[1,1'-biphenyl]-4-amine 
• 540-37-4 p-aminoiodobenzene 
• 68716-47-2 2,4-dichlorophenylboronic acid 

Relevant articles and documents

PICOLINAMIDO-PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS

The present invention is directed to picolanmido-propanoic acid derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.